Allergan Tazoral Turned Down By FDA Cmte.: Off-Label Acne Use Is Concern
Executive Summary
Concerns about potential off-label use of Allergan's Tazoral as acne therapy figured heavily in an FDA advisory committee's recommendation against approving the retinoid drug for the treatment of moderate to severe psoriasis